Skip to main content

Table 2 Orphan drugs with highest number of users, highest prices and highest budget impact (2012)

From: Orphan drugs expenditure in the Netherlands in the period 2006–2012

Rank INN Trade name Setting Patients  
1 Imatinib Glivec® Outpatient 1,485  
2 Lenalidomide Revlimid® Outpatient 1,089  
3 Sildenafil Revatio® Outpatient 1,052  
4 Thalidomide Thalidomide Cellgene® Outpatient 1,030  
5 Bosentan Tracleer® Outpatient 901  
Rank INN Trade name Setting Cost/Patient  
1 Galsulfase Naglazyme® Inpatient €600,000  
1 Idursulfase Elaprase® Inpatient €600,000  
3 Alglucosidase alfa Myzoyme® Inpatient €474,857*  
4 Eculizumab Soliris® Inpatient €358,000  
5 Aldurazyme Laronidase® Inpatient €300,000  
Rank INN Trade name Setting Budget impact (millions) Cumulative budget impact 2006–2012 (millions)
1 Alglucosidase alfa Myozyme® Inpatient €40.3 €203.4
2 Imatinib Glivec® Outpatient €36.4 €251.2
3 Lenalidomide Revlimid® Outpatient €36.2 €127.4
4 Bosentan Tracleer® Outpatient €23.0 €132.4
5 Pegvisomant Somavert® Outpatient €14.3 €72.5